Table 1 Clinical-pathological features and outcomes of patients included in the TMA analysis (N = 76)
Variables | Descriptor | Frequency N (%) |
|---|---|---|
Age | Mean | 48.4 |
BRCA mutation | Wild-type | 1 (1.3) |
Mutated | 7 (9.2) | |
Unknown | 68 (89.5) | |
Clinical staging | IA | 13 (17.1) |
IB | 2 (2.6) | |
IIA | 29 (38.2) | |
IIB | 14 (18.4) | |
IIIA | 7 (9.2) | |
IIIB | 9 (11.8) | |
IIIC | 2 (2.7) | |
Histology | IDC | 71 (93.4) |
ILC | 1 (1.3) | |
Metaplastic | 4 (5.3) | |
Histological grade | G1 | 3 (3.9) |
G2 | 27 (35.6) | |
G3 | 46 (60.5) | |
Type of treatment | Adjuvant | 62 (81.6) |
Neoadjuvant | 14 (18.4) | |
Response to Neoadjuvant chemotherapy | Complete response | 2 (14.2) |
Partial response | 6 (42.8) | |
Progressive disease | 3 (21.4) | |
Unknown | 3 (21.6) | |
Disease recurrence | Yes | 18 (23.7) |
No | 57 (75.0) | |
Unknown | 1 (1.3) | |
Disease status | Disease free | 59 (77.6) |
Disease progression | 10 (13.2) | |
Lost to follow-up | 7 (9.2) | |
Death due to cancer | Yes | 11 (14.5) |
No | 65 (85.5) |